Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 6, 2024, Wendy DiCicco's consulting agreement was terminated and she is no longer serving as Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Akari Therapeutics, Plc (the "Company") as of that date. The terms of Ms. DiCicco's separation are still being finalized and are therefore not yet available for disclosure hereunder. The Company will disclose any required severance terms in a subsequent filing to be made by the Company under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), when such terms are finalized.

On December 12, 2024, the board of directors of the Company (the "Board") approved the appointment of Samir Patel, the Company's interim Chief Executive Officer and a member of the Company's Board, to Interim Principal Financial Officer and Principal Accounting Officer, effective December 12, 2024, to serve in such capacities until such time as a new Chief Financial Officer commences employment or such other date determined by the Board. The Board has also initiated a search for a new Chief Financial Officer.

There is no arrangement or understanding between Dr. Patel and any other person pursuant to which he was selected as an officer of the Company, and there is no family relationship between Dr. Patel and any of the Company's other directors or executive officers. Dr. Patel's biography can be found in the Company's proxy statement filed with the Securities and Exchange Commission ("SEC") on June 3, 2024, which is incorporated herein by reference.